Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22393284 | 0.83 | RIPK1 (0.70) | RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL22390588 | 0.77 | RIPK1 (0.50) | RIPK1HTR2CHTR2BHTR2ASCN9A | |
| SCHEMBL22391953 | 0.77 | RIPK1 (0.61) | RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL22392894 | 0.76 | RIPK1 (0.52) | RIPK1HTR2CHTR2BHTR2ACNR2 | |
| SCHEMBL22390302 | 0.76 | RIPK1 (0.49) | RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL22389468 | 0.76 | RIPK1 (0.52) | RIPK1SCN9A | |
| SCHEMBL13547900 | 0.74 | HTR2A (0.44) | HTR2CHTR2BHTR2A | |
| SCHEMBL22391510 | 0.74 | RIPK1 (1.00) | RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL22390611 | 0.73 | RIPK1 (0.60) | RIPK1HTR2CHTR2BCNR2 | |
| SCHEMBL22393236 | 0.73 | RIPK1 (0.60) | RIPK1HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | RIPK1 1/4885HTR2C 3194/4885HTR2B 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.